{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:36:31Z","timestamp":1783550191254,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T00:00:00Z","timestamp":1497657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40265-017-0780-7","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T05:10:27Z","timestamp":1497676227000},"page":"1363-1368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Abaloparatide: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"780_CR1","unstructured":"US FDA. Tymlos\u2122 (abaloparatide) injection, for subcutaneous use: US prescribing information. 2017. \n                        https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf\n                        \n                    . Accessed 30 May 2017."},{"issue":"Suppl 1","key":"780_CR2","first-page":"M460","volume":"16","author":"MD Culler","year":"2001","unstructured":"Culler MD, Dong J, Shen Y, et al. BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential [abstract no. M460]. J Bone Miner Res. 2001;16(Suppl 1):M460.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"780_CR3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333.","journal-title":"JAMA."},{"issue":"1","key":"780_CR4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141\u20139.","journal-title":"Endocrinology."},{"key":"780_CR5","unstructured":"US FDA. Novel drug approvals for 2017. 2017. \n                        https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/druginnovation\/ucm537040.htm\n                        \n                    . Accessed 30 May 2017."},{"key":"780_CR6","unstructured":"Radius Health. Radius announces European Medicines Agency validates Marketing Authorization Application for abaloparatide-SC for the treatment of osteoporosis in postmenopausal women [media release]. 2015. \n                        http:\/\/investors.radiuspharm.com\/releasedetail.cfm?ReleaseID=945612\n                        \n                    . Accessed 30 May 2017."},{"key":"780_CR7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","volume":"86","author":"J Jolette","year":"2017","unstructured":"Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334). Regul Toxicol Pharmacol. 2017;86:356\u201365.","journal-title":"Regul Toxicol Pharmacol."},{"key":"780_CR8","unstructured":"Radius Health. Radius announces positive top-line results from completed ACTIVExtend study for TYMLOS\u2122 in postmenopausal women with osteoporosis [media release]. 2017. \n                        http:\/\/investors.radiuspharm.com\/releasedetail.cfm?ReleaseID=1027778\n                        \n                    . Accessed 30 May 2017."},{"key":"780_CR9","unstructured":"Radius Health. Radius, 3M Drug Delivery Systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for osteoporosis [media release]. 2012. \n                        http:\/\/investors.radiuspharm.com\/releasedetail.cfm?ReleaseID=838112\n                        \n                    . Accessed 30 May 2017."},{"issue":"2","key":"780_CR10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697\u2013706.","journal-title":"J Clin Endocrinol Metab."},{"key":"780_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","volume":"97","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, et al. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314\u20139.","journal-title":"Bone."},{"key":"780_CR12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","volume":"95","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone. 2017;95:143\u201350.","journal-title":"Bone."},{"issue":"1","key":"780_CR13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res. 2017;32(1):24\u201333.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"780_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, et al. Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int. 2016;99(5):489\u201399.","journal-title":"Calcif Tissue Int."},{"issue":"2","key":"780_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200\u201310.","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"780_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY, et al. Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32(1):17\u201323.","journal-title":"J Bone Miner Res."},{"key":"780_CR17","unstructured":"Saeh J, Pais D, Hamad E, et al. Clinical development of an optimized abaloparatide transdermal patch [abstract no. LB-1162]. In: 38th annual meeting of the American Society for Bone and Mineral Research. 2016."},{"key":"780_CR18","unstructured":"Radius Health. Radius Health reports first quarter 2017 financial and operating results [media release]. 2017. \n                        http:\/\/investors.radiuspharm.com\/releasedetail.cfm?ReleaseID=1023647\n                        \n                    . Accessed 30 May 2017."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0780-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T13:00:25Z","timestamp":1501074025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0780-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0780-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,17]]}}}